Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858880 | 0.92 | BACE1 (0.35) | BACE1DPP4DPP8DPP7OPRM1 | |
| SCHEMBL29181819 | 0.87 | BACE1 (0.37) | BACE1 | |
| SCHEMBL31048975 | 0.81 | BACE1 (0.42) | BACE1HCAR2 | |
| SCHEMBL23314044 | 0.81 | — | — | |
| SCHEMBL31551850 | 0.80 | BACE1 (0.41) | BACE1DPP4DPP8HCAR3HCAR2 | |
| SCHEMBL28978262 | 0.75 | BACE1 (0.42) | BACE1GLANPSR1 | |
| SCHEMBL698104 | 0.75 | BACE1 (0.43) | BACE1GLANPSR1 | |
| SCHEMBL29679997 | 0.74 | PIK3CA (0.43) | BACE1HDAC1GLANPSR1 | |
| SCHEMBL24535005 | 0.74 | PIK3CA (0.43) | BACE1HDAC1GLANPSR1 | |
| SCHEMBL29679895 | 0.74 | KDM4E (0.39) | BACE1GLANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024178304-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-11965193-B2 | Use of stereoselective transaminase in asymmetric synthesis of chiral amine | ABIOCHEM BIOTECHNOLOGY CO., LTD (CN) | 2024-04-23 | — | — | US | disclosed |
| US-20230203550-A1 | USE OF STEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE | ABIOCHEM BIOTECHNOLOGY CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203550-A1 | USE OF STEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE | ABIOCHEM BIOTECHNOLOGY CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203550-A1 | USE OF STEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE | ABIOCHEM BIOTECHNOLOGY CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| US-11499172-B2 | Use of stereoselective transaminase in asymmetric synthesis of chiral amine | ABIOCHEM BIOTECHNOLOGY CO., LTD. (CN) | 2022-11-15 | — | — | US | disclosed |
| US-20210123080-A1 | METHOD FOR BIOCATALYTIC SYNTHESIS OF SITAGLIPTIN AND INTERMEDIATE THEREOF | CHINA FORTUNE WAY COMPANY (CN) | 2021-04-29 | — | — | US | disclosed |
| CN-112195201-A | Application of stereoselective transaminase in asymmetric synthesis of chiral amine | 弈柯莱生物科技(上海)股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-110914417-B | Application of stereoselective transaminase in asymmetric synthesis of chiral amine | 弈柯莱生物科技(上海)股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3156391-B1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-20110130587-A1 | PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2011-06-02 | — | — | US | disclosed |
| EP-2308829-A1 | A PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2011-04-13 | — | — | EP | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| EP-2230241-A1 | TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-09-22 | — | — | EP | disclosed |
| EP-2230241-A1 | TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-09-22 | — | — | EP | disclosed |
| CN-101641360-A | Piperazine derivatives, preparation method and medical application thereof | SHANGHAI HENGRUI PHARM CO LTD | 2010-02-03 | — | — | CN | disclosed |
| CN-101641361-A | Tetrahydroimidazo [1, 5-a ] pyrazine derivative, preparation method and application thereof in medicine | SHANGHAI HENGRUI PHARM CO LTD | 2010-02-03 | — | — | CN | disclosed |
| US-20090124601-A1 | Tartaric Acid Salts of a Dipeptidyl Peptidase-IV Inhibitor | MERCK & CO., INC. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210123080-A1 | METHOD FOR BIOCATALYTIC SYNTHESIS OF SITAGLIPTIN AND INTERMEDIATE THEREOF | DPP4, SI, DPP9 | BACE1 185/4885MMP1 976/4885MMP2 116/4885 |
| US-20110130587-A1 | PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES | ALAD, DAO, DDO | BACE1 818/4885MMP1 4556/4885MMP2 3500/4885 |
| US-20090124601-A1 | Tartaric Acid Salts of a Dipeptidyl Peptidase-IV Inhibitor | DPP4, DPP3, DPP7 | BACE1 187/4885MMP1 178/4885MMP2 49/4885 |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | BACE1 216/4885MMP1 194/4885MMP2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.